BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25885131)

  • 1. Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.
    Singh N; Sazawal S; Upadhyay A; Chhikara S; Mahapatra M; Saxena R
    Indian J Pathol Microbiol; 2015; 58(2):187-91. PubMed ID: 25885131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
    Sazawal S; Singh N; Mahapatra M; Saxena R
    Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [JAK2V617F mutation in patients with idiopathic myelofibrosis].
    Li WD; Li JY; Zhang SJ; Qiu HR; Xu W; Wang JS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):387-90. PubMed ID: 17493353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The quantitative assay and clinical significance of JAK2V617F mutation in 131 patients with chronic myeloproliferative disorders].
    Shen YM; Chao HY; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Nei Ke Za Zhi; 2009 Feb; 48(2):140-3. PubMed ID: 19549471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
    Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.
    Tefferi A; Lasho TL; Patnaik MM; Finke CM; Hussein K; Hogan WJ; Elliott MA; Litzow MR; Hanson CA; Pardanani A
    Leukemia; 2010 Jan; 24(1):105-9. PubMed ID: 19847199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults.
    DeLario MR; Sheehan AM; Ataya R; Bertuch AA; Vega C; Webb CR; Lopez-Terrada D; Venkateswaran L
    Am J Hematol; 2012 May; 87(5):461-4. PubMed ID: 22389089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
    Iurlo A; Elli EM; Palandri F; Cattaneo D; Bossi A; Cortinovis I; Bucelli C; Orofino N; Brioschi F; Auteri G; Bianchi P; Fabris S; Isimbaldi G; Sabattini E; Baldini L; Gianelli U
    Hematol Oncol; 2019 Oct; 37(4):424-433. PubMed ID: 31359447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.
    Tefferi A; Lasho TL; Huang J; Finke C; Mesa RA; Li CY; Wu W; Hanson CA; Pardanani A
    Leukemia; 2008 Apr; 22(4):756-61. PubMed ID: 18216871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
    Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
    Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
    Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
    Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
    Kerguelén Fuentes AE; Hernández-Maraver D; Lombardia L; Canales Albendea MA; Rodriguez de la Rúa A
    Med Clin (Barc); 2012 Oct; 139(9):373-8. PubMed ID: 22743278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis.
    Machherndl-Spandl S; Sega W; Bösmüller H; Germing U; Gruber Ch; Nachtkamp K; Reinecke P; Sperr WR; Wimazal F; Müllauer L; Sotlar K; Horny HP; Tüchler H; Valent P; Krieger O
    Ann Hematol; 2014 Jan; 93(1):57-64. PubMed ID: 24241126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
    Martínez-Trillos A; Maffioli M; Colomer D; Alvarez-Larrán A; Pereira A; Angona A; Bellosillo B; Cervantes F
    Ann Hematol; 2014 May; 93(5):797-802. PubMed ID: 24337516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
    Guglielmelli P; Barosi G; Specchia G; Rambaldi A; Lo Coco F; Antonioli E; Pieri L; Pancrazzi A; Ponziani V; Delaini F; Longo G; Ammatuna E; Liso V; Bosi A; Barbui T; Vannucchi AM
    Blood; 2009 Aug; 114(8):1477-83. PubMed ID: 19549988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.